Advertisement
YOU ARE HERE: LAT HomeCollectionsGlaxo Wellcome Inc
IN THE NEWS

Glaxo Wellcome Inc

FEATURED ARTICLES
BUSINESS
October 24, 1995 | Times Staff and Wire Reports
Settlement Reached Over Zantac: British-based Glaxo Wellcome Inc. announced that it has reached an out-of-court settlement with a Canadian company, Genpharm Inc., in a patent infringement lawsuit over the world's best-selling prescription drug. Jury selection had been scheduled to begin Monday in Baltimore in a trial over the validity of two Glaxo Wellcome patents for the ulcer medication Zantac.
ARTICLES BY DATE
NEWS
November 29, 2000 | DAVID WILLMAN, TIMES STAFF WRITER
Another drug launched with "fast-track" government approval was withdrawn on Tuesday, marking the 10th time in three years that a prescription medicine has been banished in the United States for safety reasons. The drug, Lotronex, was approved nine months ago for treating irritable bowel syndrome in women. The withdrawal was announced by Glaxo Wellcome Inc. after the Food and Drug Administration received voluntary reports linking the company's drug to five deaths and additional bowel surgeries.
Advertisement
BUSINESS
February 6, 1997 | From Associated Press
Glaxo Wellcome will sell its pharmaceutical production plant in Greenville, N.C., to a medium-size California company in a deal that will save hundreds of jobs, the companies said Wednesday. Catalytica Inc. has signed a letter of intent to acquire land, buildings and equipment at the 1.8-million-square-foot site in Greenville for an undisclosed amount, the companies said in a joint announcement.
BUSINESS
February 6, 1997 | From Associated Press
Glaxo Wellcome will sell its pharmaceutical production plant in Greenville, N.C., to a medium-size California company in a deal that will save hundreds of jobs, the companies said Wednesday. Catalytica Inc. has signed a letter of intent to acquire land, buildings and equipment at the 1.8-million-square-foot site in Greenville for an undisclosed amount, the companies said in a joint announcement.
NEWS
November 29, 2000 | DAVID WILLMAN, TIMES STAFF WRITER
Another drug launched with "fast-track" government approval was withdrawn on Tuesday, marking the 10th time in three years that a prescription medicine has been banished in the United States for safety reasons. The drug, Lotronex, was approved nine months ago for treating irritable bowel syndrome in women. The withdrawal was announced by Glaxo Wellcome Inc. after the Food and Drug Administration received voluntary reports linking the company's drug to five deaths and additional bowel surgeries.
NEWS
December 10, 1998 | From Times Wire Reports
Sufferers of liver-destroying hepatitis B gained their first oral treatment: a drug that in higher doses is used to fight the AIDS virus. The Food and Drug Administration approved a lower dose of Glaxo Wellcome Inc.'s 3TC, or lamivudine, as a way to protect against the liver damage caused by chronic hepatitis B.
NEWS
August 25, 2000 | From Times Wire Reports
The government is sending to women's homes a major warning about a popular new treatment for irritable bowel syndrome: The drug Lotronex sometimes causes severe intestinal side effects--some requiring surgery--so stop taking it at the earliest sign of a problem. Hoping to help women safeguard themselves, the Food and Drug Administration announced it has ordered Glaxo Wellcome Inc. to attach to every Lotronex bottle a pamphlet explaining the risk.
BUSINESS
April 7, 1997 | Associated Press
Ulcer patients that have long relied on Zantac to ease their pains will soon have a generic alternate on the market at half the price they now pay, Novopharm USA Inc. executives said. A federal appeals court ruled Friday that the generic drug would not violate two Glaxo Wellcome Inc. patents on Zantac, which as the world's best-selling prescription medicine had sales of $1.63 billion in the United States last year.
BUSINESS
April 22, 1999 | Bloomberg News
Merck & Co., Glaxo-Wellcome Inc., Bristol-Myers Squibb Co. and 14 other drug companies will give away $148 million worth of products in California during the next three years to settle allegations they conspired to fix the price of prescription brand-name drugs. The drug makers were accused in the class-action suit of overcharging California consumers for drugs purchased through retail pharmacies since 1990.
NEWS
July 7, 1999 | From Times Wire Reports
A new drug inhaled once a day during flu outbreaks may help prevent people from becoming infected with either A or B strains, an improvement over older drugs, researchers said. According to a study in the July 7 issue of the Journal of the American Medical Assn., half of about 1,100 healthy adults inhaled 10 milligrams of zanamivir, also called Relenza, once a day for four weeks during the 1997-98 flu season. The other half were given a fake dose. Dr.
BUSINESS
October 24, 1995 | Times Staff and Wire Reports
Settlement Reached Over Zantac: British-based Glaxo Wellcome Inc. announced that it has reached an out-of-court settlement with a Canadian company, Genpharm Inc., in a patent infringement lawsuit over the world's best-selling prescription drug. Jury selection had been scheduled to begin Monday in Baltimore in a trial over the validity of two Glaxo Wellcome patents for the ulcer medication Zantac.
CALIFORNIA | LOCAL
January 30, 2001
* Homestore.com Inc. in Westlake Village has hired Richard F. Sommer, former chief executive of MedChannel Inc., as managing director / corporate senior vice president of international operations. In this newly created position, Sommer will explore opportunities to extend Homestore.com's business overseas. Homestore.com operates a network of real estate Internet sites. * * Leonard D. Schaeffer, chairman and chief executive of WellPoint Health Networks Inc.
OPINION
November 12, 2000
Re "FDA Minimized Issue of Lotronex's Safety," Nov. 2: It is untrue that Glaxo Wellcome and the FDA have not taken seriously reports of adverse events among women who have taken Lotronex. Both Glaxo Wellcome and the FDA apply the world's highest standards in our efforts to make innovative medicines available. We both have independently scrutinized the benefits and risks and have concluded that, in appropriate patients, Lotronex has a demonstrated benefit in the treatment of diarrhea-predominant irritable bowel syndrome, which can be severely incapacitating.
Los Angeles Times Articles
|